- Home
- IMPP vs CGTX Comparison
IMPP vs CGTX Comparison
Compare IMPP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMPP
- CGTX
- Stock Information
- Founded
- IMPP 1981
- CGTX 2007
- Country
- IMPP Greece
- CGTX United States
- Employees
- IMPP N/A
- CGTX N/A
- Industry
- IMPP Marine Transportation
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- IMPP Consumer Discretionary
- CGTX Health Care
- Exchange
- IMPP Nasdaq
- CGTX Nasdaq
- Market Cap
- IMPP 174.2M
- CGTX 158.8M
- IPO Year
- IMPP N/A
- CGTX 2021
- Fundamental
- Price
- IMPP $5.37
- CGTX $1.57
- Analyst Decision
- IMPP Strong Buy
- CGTX Strong Buy
- Analyst Count
- IMPP 1
- CGTX 3
- Target Price
- IMPP $5.50
- CGTX $2.83
- AVG Volume (30 Days)
- IMPP 554.7K
- CGTX 1.8M
- Earning Date
- IMPP 12-01-2025
- CGTX 11-07-2025
- Dividend Yield
- IMPP N/A
- CGTX N/A
- EPS Growth
- IMPP N/A
- CGTX N/A
- EPS
- IMPP 1.02
- CGTX N/A
- Revenue
- IMPP $127,675,263.00
- CGTX N/A
- Revenue This Year
- IMPP $9.69
- CGTX N/A
- Revenue Next Year
- IMPP $51.33
- CGTX N/A
- P/E Ratio
- IMPP $5.28
- CGTX N/A
- Revenue Growth
- IMPP N/A
- CGTX N/A
- 52 Week Low
- IMPP $2.12
- CGTX $0.22
- 52 Week High
- IMPP $5.78
- CGTX $3.83
- Technical
- Relative Strength Index (RSI)
- IMPP 67.31
- CGTX 44.00
- Support Level
- IMPP $5.18
- CGTX $1.53
- Resistance Level
- IMPP $5.49
- CGTX $1.78
- Average True Range (ATR)
- IMPP 0.34
- CGTX 0.13
- MACD
- IMPP 0.04
- CGTX -0.03
- Stochastic Oscillator
- IMPP 75.35
- CGTX 4.26
About IMPP Imperial Petroleum Inc.
Imperial Petroleum Inc is a provider of international seaborne transportation services to oil producers, refineries, and commodities traders. It owns and operates a fleet of six medium-range product tankers that carry refined petroleum products such as gasoline, diesel, fuel oil, and jet fuel, as well as edible oils and chemicals.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.